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Abstract
Background: Growth hormone is an important regulator of post-natal growth and metabolism. We have investigated the
metabolic consequences of altered growth hormone signalling in mutant mice that have truncations at position 569 and
391 of the intracellular domain of the growth hormone receptor, and thus exhibit either low (around 30% maximum) or no
growth hormone-dependent STAT5 signalling respectively. These mutations result in altered liver metabolism, obesity and
insulin resistance.
Methodology/Principal Findings: The analysis of metabolic changes was performed using microarray analysis of liver tissue
and NMR metabonomics of urine and liver tissue. Data were analyzed using multivariate statistics and Gene Ontology tools.
The metabolic profiles characteristic for each of the two mutant groups and wild-type mice were identified with NMR
metabonomics. We found decreased urinary levels of taurine, citrate and 2-oxoglutarate, and increased levels of
trimethylamine, creatine and creatinine when compared to wild-type mice. These results indicate significant changes in lipid
and choline metabolism, and were coupled with increased fat deposition, leading to obesity. The microarray analysis
identified changes in expression of metabolic enzymes correlating with alterations in metabolite concentration both in
urine and liver. Similarity of mutant 569 to the wild-type was seen in young mice, but the pattern of metabolites shifted to
that of the 391 mutant as the 569 mice became obese after six months age.
Conclusions/Significance: The metabonomic observations were consistent with the parallel analysis of gene expression and
pathway mapping using microarray data, identifying metabolites and gene transcripts involved in hepatic metabolism,
especially for taurine, choline and creatinine metabolism. The systems biology approach applied in this study provides a
coherent picture of metabolic changes resulting from impaired STAT5 signalling by the growth hormone receptor, and
supports a potentially important role for taurine in enhancing b-oxidation.
Citation: Schirra HJ, Anderson CG, Wilson WJ, Kerr L, Craik DJ, et al. (2008) Altered Metabolism of Growth Hormone Receptor Mutant Mice: A Combined NMR
Metabonomics and Microarray Study. PLoS ONE 3(7): e2764. doi:10.1371/journal.pone.0002764
Editor: Yihai Cao, Karolinska Institutet, Sweden
Received November 24, 2006; Accepted June 26, 2008; Published July 23, 2008
Copyright:  2008 Schirra et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Australian Research Council (ARC) and the National Health and Medical Research Council (NHMRC). HJS is a
Queensland Smart State Fellow. DJC is an ARC Professorial Fellow. MJW is a NHMRC Senior Principal Research Fellow. The 700 MHz wide-bore NMR spectrometer
is part of the Queensland NMR Network, which was established with funding from the Queensland State Govenment.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: h.schirra@uq.edu.au
¤ Current address: TessArae LLC, Potomac Falls, Virginia, United States of America
Introduction
Growth hormone (GH) is both the major regulator of postnatal
growth and an important metabolic regulator, influencing many
aspects of lipid, carbohydrate, and protein metabolism [1]. GH
exerts its anabolic actions by increasing lean body mass and
decreasing adiposity. These actions are mediated largely by
increased protein synthesis, decreased proteolysis, inhibition of
insulin-stimulated adipogenesis and induction of lipolysis [2–7].
Treatment with GH also affects hepatic glucose metabolism,
mostly through the stimulation of gluconeogenesis [8]. A large
number of other physiological processes are affected by GH,
including drug and xenobiotic metabolism through the regulation
of P450 cytochrome expression [9].
GH acts through its receptor on the cell surface, which is a
cytokine class I receptor with multiple tyrosines on the intracellular
domain. Binding of the hormone to the receptor induces receptor
tyrosine phosphorylation with intracellular signaling through a
number of pathways, such as signal transducer and activator of
transcription 5 (STAT5), Mitogen-activated protein kinase
(MAPK), Phosphoinositide-3 kinase (PI3K) and Janus kinase 2
(JAK2) [10,11], leading to differential gene expression and changes
in physiological response. While the role of GH in metabolism has
been studied in a number of animal models and in humans
undergoing GH therapy [12–16], the contribution of individual
pathways to metabolism remains unclear. Treatment of GH-
deficient adults or the elderly has been shown to normalize the
altered body composition seen in GH deficiency, including
PLoS ONE | www.plosone.org 1 July 2008 | Volume 3 | Issue 7 | e2764increased fat mass, decreased muscle mass and decreased bone
mineral density. Transcript changes associated with these metabolic
alterations have been studied in animal models, but the full extent
and physiological consequences of the altered transcript profiles are
not clear [15,17,18]. Recently, we have described growth hormone
receptor (GHR) mutant mice, with truncations of the intracellular
domain of the GHR at position 569 and 391 [19]. These truncations
lead to altered signaling through the GHR in response to hormone
binding and allow us to study the contribution of particular GH
receptor signaling domains to gene expression and metabolism. In
particular, these mouse strains exhibit variable levels of STAT5
signalling in response to GH stimulation (Figure 1) and show
substantial alterations in hepatic gene expression, together with
growth deficit and later onset obesity.
The microarray analysis in our previous study focused on the
genes involved in GH enhancement of postnatal growth. We
identified sets of genes regulated by particular signaling pathways
with a major focus on STAT5 targets. However, there was little
analysis of how this differential gene expression affects metabolism
in the GHR mutant mice. As GH regulates metabolism in many
ways, we were interested in identification of the actual metabolic
changes that relate to the development of obesity and insulin
resistance in our mice. However, changes in gene expression do
not directly measure metabolic changes, and mapping of the
differentially expressed genes onto metabolic pathways only
provides an indication of pathways that can be affected, without
defining the actual metabolic consequences. Therefore there was a
need to use an alternative method to assess the global metabolic
changes and their time course to determine the likely causes of
observed phenotypic changes in our mouse model.
Any significant perturbation of metabolism, such as the one
caused by the GHR mutations, is reflected in the composition of
body fluids such as urine, blood or saliva, which yield a different
‘‘metabolic fingerprint’’ for each metabolic state [20]. Conse-
quently, valuable information about metabolic changes can be
obtained by monitoring global changes in the composition of
biofluids of various populations or individuals [20]. The
experimental approach enabling this is metabonomics and has
been defined as ‘‘the quantitative measurement of the dynamic
multiparametric metabolic response of living systems to patho-
physiological stimuli or genetic modification’’ [21]. As it is able to
analyze global metabolic changes in biofluids it is an appropriate
tool for comparing GHR mutant mouse models and allows us to
integrate metabolite data with our previous microarray study [19].
Nuclear magnetic resonance (NMR) spectroscopy is one of the
major techniques used in metabonomic studies. The advantage of
using NMR over other techniques such as mass spectroscopy is that
it requires only minimal sample preparation, is non-destructive and
inherently quantitative [20]. NMR spectra possess a wealth of
metabolic information, containing signals from thousands of
individual metabolites that are observed simultaneously and that
can partially overlap. Because of the information density of NMR
spectra, data are routinely analysed by a combination of data
reduction and pattern recognition methods using multivariate
statistical analysis, such as principal components analysis (PCA) or
partial least squares discriminant analysis (PLS-DA) [22]. This
strategy results in identification of groups with similar metabolic
patterns. In addition, individual metabolites discriminating between
these experimental groups can be identified.
The aim of this study was therefore to identify metabolic
changes in our GHR mutant mice by analysis of urinary and
hepatic metabolites and to correlate these changes with tran-
scriptome-based pathway analysis to establish metabolic pathways
affected by the extents of differential STAT5 signalling. This is to
our knowledge the first study linking the analysis of transcriptional
changes based on microarrays with metabonomic analysis of
actual metabolite changes in strains of receptor mutant mice. Our
approach has allowed us to identify key metabolites and altered
pathways, which provide a coherent and complementary picture
of physiological changes at the level of the whole organism in
relation to the metabolic role of GH.
Results
Growth hormone receptor (GHR) modifications in vivo:
In this study we used animals previously generated in our
laboratory with characterized mutations in the intracellular domain
of the GHR [19] (Figure 1). Our previous study showed that their
hepatic response to GH administration is impaired in relation to the
extent of STAT5 signalling, with mutant 569 showing 30% of the
wild-type response, while mutant 391 has no STAT5 signalling
response [19]. At the same time both mutants have shown normal
activation of JAK2, MAPK and STAT3 signalling, and microarray
comparison with mice harboring complete GH receptor deletion
showed most GH-regulated transcripts do not involve STAT5
signalling. Thus, in this study we determined the metabolic
consequences of the loss in GHR signalling from the distal portion
of the GH receptor, including total loss of STAT5 signalling.
Adipose accumulation:
The most striking physiological and phenotypic change in the
mutant animals is a dramatic increase in weight, resulting from
obesity (Figure 2B–E). The weight of all mutants and wild-type
littermates up to 21 days of age was not significantly different [19].
The body weight differentiated in the following 2 months, and was
in both sexes significantly lower for each of the 569, 391 and
GHR
2/2 mutants than for their wild-type littermate controls at 2
months of age ([19], Figure 2C). However, over the next 4 months
the weight of the mutant 569 mice increased, so that at 6 months
the difference with the wild-type was no longer statistically
significant, and later mutant 569 mice became significantly
heavier. While the weight of the 391 mutant mice was essentially
Figure 1. Structure of the intracellular domain of the Growth
Hormone Receptor (GHR). The mutations in the GHR have been
made in the intracellular domain (ICD) of the receptor. (A) The wild-type
has intact signaling through JAK2, MAPK and STAT5. (B) In mutant 569
the ICD has been truncated at residue 569 and two distal tyrosines were
mutated to phenylalanines resulting in only 30% of wild-type STAT5
signaling in response to GH. (C) Mutant 391 has been truncated at
residue 391 and has no STAT5 signaling ability, while normal JAK2 and
MAPK signaling is maintained.
doi:10.1371/journal.pone.0002764.g001
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were also significantly shorter than wild-type mice as evident in
Figure 2B, and thus became severely obese at a lower body weight.
The observed increase in weight reflected an increased fat
deposition for all mutant mouse strains. Indeed, when the fat
accumulation was analyzed over time at 2, 4, 10 and 13 months
(Figure 2D and E), there was a significant difference between the
mutants and the wild-type. This difference is especially pro-
nounced in the subcutaneous fat deposits, which is expected, as
subcutaneous fat pads have been shown to be the deposit most
sensitive to GH regulation in rodents [23]. While the wild-type
mice showed only a small increase in subcutaneous fat up to 13
months of age, the 391 mutants began to accumulate subcutane-
ous fat from early in their life reaching a maximum at 10 months
of age (Figure 2D). The 569 mutant showed a slower, more
constant increase of subcutaneous fat and by 13 months of age
almost reached that of the 391 mutant. The picture changes only
slightly when the perirenal fat deposits are viewed (Figure 2E).
While the wild-type exhibited only a slow increase in the
percentage of dissectable body fat, all mutants accumulated fat
very rapidly after 2 months of age, with the 569 mutant displaying
a rate of perirenal fat accumulation that was similar to the
GHR2/2 mutant and slightly faster than the 391 mutant
(Figure 2E).
Metabolic pathway analysis and identification of marker
genes in microarray data
To investigate the biological processes underlying this dramatic
change in phenotype, we determined the effects of the GHR
mutations and altered STAT5 signalling on transcript expression
in liver tissue of 42-day old mice, In a first round of analysis, we
used the MAS 5.0 algorithm and fold changes with a cut-off of 1.5-
fold to identify differentially expressed genes. These were
subsequently analysed by ANOVA to identify predictor genes
able to separate the four classes of microarray data (wild-type,
mutant 569, 391 and GHR
2/2) [19]. This generated a list of 20
genes regulated concordantly in all mutant mice and additional 31
genes differentially expressed between the individual mutant
groups. However, as this analysis was a supervised approach, we
wanted to use an unsupervised multivariate statistical method
Figure 2. Identification of marker genes differentiating between the groups and physiological characterisation of GHR mutant
mice. (A) A heatmap of classifier gene expression in liver tissue of wild-type and GHR mutant mice at 42 days age from the GeneRaVE analysis,
clustered according to similarity of expression. Gene expression has been represented as a scale between red and blue, with red indicating over
expression and blue representing under expression. Gene abbreviations are used according to current nomenclature. (B) A picture of 10 month old
male mice used in this study. (C) The weight curves of male mice from 2 months to 10 months. (D) Subcutaneous fat accumulation of male mice from
2 months to 13 months. (E) Perirenal fat accumulation of male mice from 2 months to 13 months. (C-E) green=wild-type, red=mutant 569,
blue=mutant 391, black=GHR2/2.
doi:10.1371/journal.pone.0002764.g002
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round of analysis we therefore used GeneRaVE as a method to
identify the classifier genes differentiating the groups and explore
gene interactions using network analysis.
GeneRaVE identified three genes as differentiating the groups,
RCK/p54, Hsd3b5 and Es31, whose expression levels can separate
the four classes with 84% accuracy. Subsequent classifier genes
from 11 rounds of selection were extracted from the dataset and
are shown in Figure 2A. Among these were transcripts increased in
the wild-type mice, such as cysteine sulfinic acid decarboxylase
(Csad), esterase 31 (Es31), hydroxysteroid dehydrogenase-5,
delta,5.-3-beta (Hsd3b5), hydroxysteroid (17-beta) dehydroge-
nase 2 (Hsd3b2) and kidney expressed gene 1 (Keg1) as well as
transcripts decreased in the wild-type, such as sulfotransferase
family 2A, dehydroepiandrosterone (DHEA)-preferring, member
2( Sult2a2), flavin containing monooxygenase 3 (Fmo3), hydro-
xyacid oxidase (glyoxylate oxidase) 3 (Hao3), cytochrome P450,
family 2, and subfamily b, polypeptide 9 (Cyp2b9). The only genes
not identified as biomarkers in our previous approach were Ghr,
Rck, Fmo3 and Dbp. In addition, Hsd3b2, Fos, H19, Mt1 and Igfbp1,
were differential in our previous study [19], but not reported.
Based on these results we predicted taurine as one of the
metabolites that would differentiate between the groups, as the
mRNA levels of the key enzyme involved in its biosynthesis, Csad,
were reduced in mutant 391 and GHR
2/2. In contrast, the possible
metabolic effects of changes in genes encoding other enzymes were
not immediately obvious. It was also clear from this analysis that at
42 days of age the hepatic expression pattern of the mutant 569 was
very similar to that of the wild-type, and it was expected that these
mice would have very similar metabolic profiles.
GeneRaVE [24] identified several sets of genes that could be
used to discriminate the different strains of mice under study.
Individually they represent classifiers, but taken together they
represent a group of genes whose expression has been altered in
the different mouse strains in comparison to the wild-type.
However, this still did not clarify which biological pathways and
processes are affected in the GHR mutant mice.
To further characterize the pathways affected in the mutant mice
and to determine how the physiological response was changed, we
used Gene Ontology analysis and pathway mapping. Gene
Ontology (GO) analysis using NetAffx GO Browser identified that
228 (57.3%) out of 398 genes differentially expressed between the
strains were involved in metabolism, with a number of biological
processes identified. The most prominent processes affected were
generation of precursor metabolites and energy metabolism, lipid
metabolism, nucleic acid metabolism, biopolymer metabolism and
sulfur metabolism (Table 1). In addition to these metabolic processes
and those identified in [19], inflammatory response was identified as
significantly altered. Further breakdown of affected biological
processes was possible using the DAVID Functional Annotation
Tool [25], which identified 55 biological processes with a p-
value,0.05 and a minimum of 4 genes present. The 15 top
biological processes altered in GHR mutant mice as identified by
DAVID are shown in Table 2.
While gene ontology (GO) analysis and functional annotation
were pointing consistently to differences in metabolic responses
between the mouse groups, they did not indicate which individual
pathways were affected. Therefore we used pathway mapping to
identify these. In addition to functional classification, DAVID
mapped the genes successfully to pathways (Table 3). In addition,
we also performed pathway mapping using Pathway Miner
(http://www.biorag.org). This analysis indicated major changes
in multiple pathways, including xenobiotic metabolism, comple-
ment cascades, glutathione, tricarboxylic acid (TCA) cycle, fatty
acid metabolism and others (Table 3). It is clear that some
pathways were identified with both tools, while others were only
identified with one. One of the reasons for such discrepancies is
that both tools have not managed to map many of the
differentially expressed genes. DAVID has mapped only 33% of
input genes to the pathways in the Kyoto Encyclopedia of Genes
and Genomes (KEGG) data base, while Pathway Miner mapped
17% of input genes to the KEGG pathways. This highlights the
insufficiencies in analysis using pathway mapping and GO analysis
and a need for an alternative method of analysis of metabolism.
NMR-based metabonomics provides this alternative, as it
integrates the responses of all different organs to the altered
GHR signalling on a whole-body level and thus offers a direct,
cost-effective and non-invasive avenue to monitor actual metabolic
Table 1. Gene Ontology analysis of differentially expressed
genes (equal or .1.5-fold) using NetAffx Gene Ontology
Browser.
Biological Process
%o f
genes
involved
Number
of genes
Total
number
of genes
in process
Probability
value*
Generation of precursor
metabolites and energy
9.6 54 562 2e–16
Lipid metabolism 8.6 50 577 1.7e–12
Biopolymer metabolism 1.8 65 3531 5.1e–11
Catabolism 7.5 41 542 7.6e–8
Nucleic acid metabolism 1.9 51 2599 1.2e–6
Inflammatory response 11 12 109 1.6e–5
Carbohydrate metabolism 5.6 22 391 0.02
*Probability value – the likelihood of this over-representation by chance.
doi:10.1371/journal.pone.0002764.t001
Table 2. Top 15 metabolic processes identified among the
differentially expressed metabolic genes using DAVID
Functional Annotation Tool.
Biological Process Number of genes % p-value
1 generation of precursor metabolites
and energy
47 10.8 1.95e–
11
2 electron transport 34 7.8 1.4e–9
3 steroid biosynthesis 12 2.8 3.3e–6
4 catabolism 35 8 1.8e–5
5 cellular lipid metabolism 29 6.6 2.2e–5
6 biosynthesis 57 13.1 2.5e–5
7 coenzyme metabolism 17 3.9 2.7e–5
8 lipid metabolism 32 7.3 2.7e–5
9 lipid biosynthesis 18 4.1 4.1e–5
10 steroid metabolism 15 3.4 4.7e–5
11 cellular catabolism 29 6.6 1.2e–4
12 cofactor metabolism 17 3.9 1.3e–4
13 sulfur metabolism 9 2.1 2.1e–4
14 general metabolism 209 47.9 4.2e–4
15 cellular biosynthesis 48 11 4.4e–4
doi:10.1371/journal.pone.0002764.t002
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NMR metabonomics to provide a global metabolite analysis of the
GHR mutant mice.
NMR spectra of mouse urine
500 MHz one-dimensional (1D) proton NMR spectra of urine
from wild-type mice (n=16) and GHR mutant mice (n=39) were
compared. Urine from GHR
2/2 mice was not analyzed with
NMR spectroscopy because of difficulties in obtaining samples
from those animals. Only a few systematic differences were
detected by visual inspection, as can be seen in the comparison of
urine spectra at four months of age, depicted in Figure 3. The
chemical compounds present in the urine samples were assigned
on the basis of previously published chemical shift data [26,27],
data available in small metabolite data bases (http://mdl.imv.liu.
se, http://www.hmdb.ca, http://www.bmrb.wisc.edu), and addi-
tional information obtained from high-resolution homo- and
heteronuclear two-dimensional (2D) correlation spectra of repre-
sentative urine samples of the wild-type and 391 mouse strains. To
facilitate chemometric analysis and to reduce the complexity of the
NMR spectra, all 1D spectra were data reduced to integral
segments (‘‘buckets’’) with a width of 0.05 ppm.
Principal Components Analysis of urinary data
Principal components analysis (PCA) is a standard technique of
pattern recognition and multivariate data analysis. The technique is
particularly suited to the analysis of a set of data where each
individual measurement contains itself a multitude of data – as is the
case in a series of NMR spectra, containing signals from hundreds of
individual metabolites. PCA compares all measurements with each
other and explains the variation inherent in the data set in terms of
artificial components called principal components (PCs). The first
principal component (PC1) is reponsible for the largest amount of
variation in the data, the second principal component is orthogonal
to PC1 and explains the largest amount of yet unexplained variation,
and so forth with higher PCs. In effect, the first two PCs explain the
vast majority of variation present in the data. In the resulting scores
plot(Figure4A),eachdatapointcorrespondstooneNMRspectrum,
and the position in the plot is determined by the difference of that
spectrum with respect to the average of the respective PC.
Essentially, the closer points are to each other the more similar the
corresponding spectraare. Thisfeature allowsone torecogniseeasily
ifthedataformseveraldistinctgroupsorareallsimilartoeachother.
In the corresponding loadings plot (Figure 4B) each data point
correspondsto onespectral region (=bucket), and the position inthe
plot is equivalent to the correlation coefficient of that bucket with the
corresponding PC. This means that it is possible to identify from the
loadings plot which spectral regions and thus which chemical
compounds are responsible for any grouping of data points observed
in the scores plot. Loadings coefficients (=correlation coefficients) of
0 mean no correlation, and loadings coefficits of 1 mean total
correlation is observed between a particular bucket (=chemical
compound) and the variation in the corrresponding dimension. As
can be seen from Figure 4B, the loadings coefficients for most
spectral regions cluster around zero, indicating that concentration
changes in the metabolites corresponding to these regions are
insignificant. However, a number of spectral regions are clear
outliers in the loadings plot, indicating that concentration changes in
the corresponding metabolites are significantly associated with the
variation/separationobserved inthescoresplotinthecorresponding
PC. Due to their nature as correlation coefficients the loadings
coefficients are not directlyassociated with foldchanges.Theyrather
indicate, which concentration changes are significant, irrespective of
the actual magnitude of change.
PCA was performed on urine to find if it was possible to
distinguish the three different mouse strains on the basis of their
NMR spectra. A preliminary PCA showed that the urine samples
were contaminated by ethanol, possibly from sterilisation of the
urine collection vials (data not shown). Thus, a second data
reduction and PCA was performed, in which the spectral regions
containing ethanol signals were excluded. The PCA scores plot of
the first two principal components (Figure 4A) showed consider-
able clustering of the three groups, albeit with some overlap
Table 3. Pathways in the Kyoto Encyclopedia of Genes and Genomes (KEGG) database analysed using DAVID Functional
Annotation Tool and Pathway Miner.
Pathway DAVID Pathway Miner
Number of genes % p-value 569 391 GHR
2/2
Metabolism of xenobiotics 12 2.8 8.8e–5 4.4e–3 9.9e–4 4.3e–3
Complement and coagulation cascades 13 3 8.9e–5 3.5e–4 7e–5 1e–4
Gluthathione 9 2.1 3.04e–4 2.6e–3 4.3e–3 1.3e–3
TCA 7 1.6 9.2e–4 ns 1.7e–2 1.3e–2
Fatty Acid metabolism 8 1.8 2.8e–3 Not identified
Valine, Leucine and isoleucine 8 1.8 2.8e–3 ns 3e–2 ns
Androgen and estrogen metabolism 7 1.6 3.7e–3 Not identified
Proteasome 6 1.4 1.5e–2 Not identified
Arachidonic acid metabolism 8 1.8 1.9e–2 ns 4.5e–3 ns
Oxidative phosphorylation 11 2.5 2e–2 ns 1.8e–2 0
Propanoate metabolism 5 1.1 3.4e–2 ns 1.6e–2 ns
Glycine, serine and threonine metabolism 6 1.4 3.9e–2 ns 3.5e–2 1.6e–2
Lysine degration 6 1.4 4.7e–2 Not identified
Bile acid biosynthesis 5 1.1 4.9e–2 2.1e–2 4.5e–3 ns
ns: non significant
doi:10.1371/journal.pone.0002764.t003
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separated from wild-type mice, with mice from the 569 strain
exhibiting a distribution in between these two extremes. The
separation between the three groups was mostly along PC2.
Partial Least Squares-Discriminant Analysis of urinary
data
To maximise separation between the three mouse strains a
partial least squares-discriminant analysis (PLS-DA) was per-
formed. In contrast to PCA, which is an unsupervised multivariate
statistical classification method that works to explain maximum
variation between samples, PLS-DA is a supervised method that
explains maximum separation between pre-defined classes (e.g.
genotype or health state) in the data. Thus, the class membership
of each sample must be known and is provided in form of a Y-
table. PLS-DA then performs a regression of the original data
against the Y-table to maximise separation between the individual
classes. In our case, the group identity of the three mouse strains
was used in the Y-table. The PLS-DA scores plot of the first two
partial least squares (PLS) components, PLS1 and PLS2,
(Figure 4C) showed improved separation of the three mouse
strains compared to the PCA. Again, mice from the 391 strain are
completely separated from the wild-type strain, with mice from the
569 strain exhibiting a distribution in between these two extremes.
The separation between the three groups was mostly along PLS1,
suggesting that this PLS component contains metabolites associ-
ated with differences between the three strains.
The equivalent loadings plot showed several spectral regions
that exhibit significant correlation with PLS1 and/or PLS2
(Figure 4D). The chemical compounds corresponding to the
NMR signals in these regions were identified as described above.
The components most strongly associated with PLS1 and PLS2
are taurine, trimethylamine (TMA) and trimethylamine-N-oxide
(TMAO). Taurine was less prominent in the spectra of the 391
and 569 mutants than in the wild-type mice. In contrast TMA and
TMAO were present in higher concentrations in the spectra of the
mutant mice as compared to the wild-type. Other compounds
discriminating between the three strains were creatine, creatinine,
allantoin, and hippurate, all of which increased in the mutant
mice. In contrast, the concentrations of citrate and 2-oxoglutarate
were decreased in the mutant mice. Other compounds with
significant loadings coefficients in PLS1 or PLS2 that could be
identified are listed in Table 4 and indicated in Figure 4B and D.
In addition to the PLS-DA comprising all three mouse
genotypes (Figure 4C–D), two-way PLS-DAs were performed
with all possible pairwise comparisons of the genotypes (data not
shown). These analyses confirmed that especially the mutant 391
strain is completely separated from the wild-type mice, while the
569 mutant mice are more similar to the 391 mutant mice than the
wild type especially with age. As expected, essentially the same
metabolites that are responsible for the differences between all
three genotypes were with minor differences also significant for
discriminating between groups in the two-way comparisons (as
shown in Table 4).
Figure 3. 1D proton NMR spectra of mouse urine at 298 K. Spectra of one individual of four months age from each mouse strain are shown.
Top: wild-type, middle: 569 mutant, bottom: 391 mutant. The identity of relevant metabolites is indicated above each spectrum.
doi:10.1371/journal.pone.0002764.g003
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PLoS ONE | www.plosone.org 6 July 2008 | Volume 3 | Issue 7 | e2764Figure 4. Statistical analysis of metabolites in mouse urine. (A) Principal components analysis - scores plot of PC1 versus PC2. Each data point
represents one mouse urine sample, and the distance between points in the score plot is an indication of the similarity between samples. Green
circles: wild-type, red squares: 569 mutants, blue triangles: 391 mutants. The borders of the groups are also highlighted by lines in the corresponding
colors. (B) Principal components analysis - loadings plot of PC1 versus PC2. Each data point represents one bucket (with the chemical shift indicated
explicitly). The plot indentifies which spectral regions (and thus which chemical compounds) are responsible for the differences between the spectra
observed in the scores plot. The loadings coefficients in each dimension are correlation coefficients that indicate how strongly each metabolite is
correlated with the observed variance in the respective dimension. t=0 means no correlation, and t=1 means total correlation. Several significant
metabolites are indicated explicitly. 2-OG: 2-oxoglutarate, DMA: dimethylamine, TMA: trimethylamine, TMAO: trimethylamine-N-oxide. The model
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391 mutants in the PLS-DA scores plot remain constant, the
position of the 569 mutant mice is clearly dependent on the age of
the mice: The samples of the younger 569 mutant mice with an
age up to 6.5 months cluster in the PLS1-PLS2 scores plot in the
metabolic space close to the wild-type mice (Figure 4C), while the
urine samples of older 569 mice between 9 and 12 months of age
cluster in the area of the 391 mutant mice. From the average PLS
scores of mice of similar age it was possible to construct metabolic
trajectories for the three mouse strains as shown in Figure 4E. This
graph reveals the same picture with even grater clarity: The
metabolism of the wild-type and 391 mutant mice remains
essentially unchanged with age, while the metabolism of the 569
mutant mice changes from a wild-type like metabolism in young
mice to a 391 mutant-like metabolism after 6 months of age,
associated with the onset of obesity.
Principal Components Analysis of murine liver tissue
After establishing the effects of the GHR mutations on the
metabolite profile of mouse urine we wanted to determine if these
mutations manifest in the metabolite profile of liver, as this was the
subject of the microarray analysis and a major GH target tissue.
We specifically wanted to compare the taurine status in the livers
of wild-type mice to their counterparts from the 569 and 391
mutants, as taurine status relates to obesity [28] (see below) . In
addition, we included obese wild-type animals fed on a high-fat
diet to distinguish effects caused by obesity from the effects caused
by the GHR mutations.
700 MHz 1D high-resolution magic angle spinning (HR-MAS)
proton NMR spectra of intact liver tissue from four months old
wild-type mice (n=6), mutant 569 mice (n=3), mutant 391 mice
(n=6), and wild-type mice fed on a high-fat diet (n=3) were
measured. An example spectrum is shown in Figure 5A.
A preliminary PCA of liver tissue spectra was dominated by the
signals of lactate and glutamate/glutamine, which changed
disproportionately in intensity and chemical shift (data not shown).
Thus, a second data reduction and PCA was performed, in which
the spectral regions containing these signals were excluded. The
PCA scores plot of PC1 versus PC2 (Figure 5B) showed
considerable clustering of the four groups of mice, albeit with
consists of 7 PCs and represents data from 48 samples. Regions containing water, urea, and ethanol signals were excluded from the PCA. (C) Partial
Least Squares-Discriminant Analysis - scores plots of PLS1 versus PLS2. The coding of groups is same as in panel (A). (D) Partial Least Squares-
Discriminant Analysis - loadings plot of PLS1 versus PLS2. The chemical shift of each bucket as well as selected metabolites are indicated explicitly.
Abbreviations as in panel (B). (E) Metabolic trajectories of the three mouse strains. Depicted is the change in the first PLS component PLS1 with the age
of the mice. The mean metabolic trajectories (obtained by averaging the PLS1 scores of mice with similar age) are indicated by thick lines. The wild-
type trajectory is colored green, the 569 mutant red, and the 391 mutant blue. The 2s standard deviation from each mean trajectory is indicated by
areas shaded in the respective color. As can be seen, the metabolic trajectory of the 569 mutant mice moves with age from the position of the wild-
type mice to the position of the 391 mutant mice.
doi:10.1371/journal.pone.0002764.g004
Table 4. Identified metabolites with significant loadings coefficients in the first three PLS components t1 to t3.
Metabolite
1H chemical shifts [ppm] multiplicity /
13C chemical shifts[ppm]
a Increase (+) or decrease (2)i n :
m./wt
bc 569/wt
c 391/wt
c 391/569
c
Taurine 3.43t / 35.6; 3.27t / 47.5 22 22 22 22
Trimethylamine (TMA) 2.88s / 44.6 ++ ++ ++ 22
Hippurate 7.84d / 122; 7.64t / 127; 7.56t / 123; 3.97d / 43.8 ++ + ++ ++
Allantoin 7.36m / 124; 5.39s / 63.6 ++ 0 ++ ++
Creatinine 4.06s / 56.2; 3.05s / 30.1 + + ++ ++
Creatine 3.94s / 53.9; 3.04s / 36.8 ++++
Isethionic acid 3.96t / 57; 3.17t / 52.7 ++++
TMAO 3.28s / 59.5 22 0 22 22
Citrate 2.69d / 44.5; 2.55d / 44.5 2222
2-Oxoglutarate (2-OG) 3.02t / 29.9 22 2 22
Oxaloacetate 3.37s / 48.7 22 000
Succinate 2.41s / 34.1 2200
Dimethylamine (DMA) 2.72s / 34.4 0 + 0 2
Methylamine 2.61s / 24.7 0 0 0 0
3-Hydroxybutyrate 2.45t / 44.2; 1.25d / 21.9 2220
Fatty Acid 2.30t / 35.6; 1.64m, 1.63m, 1.61m / 24.9; 1.60m, 1.59m; 0.88t / 15.2 22 2 22 ++
Valine 2.06m / 26.6; 0.94d / 21.5 2220
Isoleucine 0.93t / 12.8 2220
achemical shifts in ppm denote the position of a signal in the NMR spectra, the multiplicity describes the coupling pattern of a NMR signal, s: singlet, d: doublet, t: triplet,
m: multiplet. These data were used for metabolite identification.
bm.: mutants, wt: wild-type.
ct1 to t3 are the loadings coefficients (=correlation coefficients) for each metabolite in the first three PLS-DA dimensions. t=0 means no correlation between
metabolite and variance in the respective dimension, and t=1 means total correlation. For the majority of metabolites, t is between 20.1 and 0.1. ++:t .0.2, +:
0.1,t,0.2, 0: 20.1,t,0.1, 2: 20.2,t,20.1, 22:t ,20.2.
doi:10.1371/journal.pone.0002764.t004
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urine, the 391 mutant mice were clearly separated from wild-type
mice, with the 569 mutants exhibiting a distribution encompassing
these two extremes. The spectra of the high-fat diet wild-type mice
also form a separate group, distinct from both the lean wild-type
and 391 mutant mice. The separation between these groups was
mostly along PC1. The loadings plot (Figure 5C) reveals that the
buckets associated with taurine (d=3.20–3.50 ppm) are the most
significant descriptors associated with this group separation. It
indicates that on average taurine levels are decreased in the liver
tissue of the 391 mutant mice as compared to the wild-type. This
parallels the result obtained in the multivariate analysis of mouse
urine. In contrast, taurine levels are increased in obese wild-type
mice fed on a high-fat diet when compared to their lean
counterparts (Figure 5BC).
Discussion
In this paper we have shown that metabonomics can identify
significant metabolic changes in animal models exhibiting altered
signalling by the growth hormone receptor and that these changes
correlate with altered expression of key metabolic enzymes in the
liver, the major GH target organ. While both metabonomics and
microarrayapproachesareverydifferent,bothallowedidentification
of groups of animals according to their genotype. This was achieved
by using multivariate statistical tools, which identified markers
(metabolitesandgenes)correlatingwithaparticulargenotype.Asthe
strains of mice used in this study have the same C57Bl/6J
background and differ only in the GHR sequence [19] (Figure 1),
the metabolic differences observed can be exclusively attributed to
the effects induced by mutations in the GHR associated with
differential signalling in response to GH. While the altered
transcripts identified by microarrays are useful, it was important to
understand how they affect the physiological outcome of the
mutations in the GHR mutant mice. This aim was achieved by
combining Gene Ontology analysis, pathway mapping and
metabonomic data to generate a global image of metabolic changes
in these mice (Supplementary Information Figure S1).
The observed separation of the mouse strains in PCA, PLS-DA
and GeneRaVE, reflects the observed phenotype and gene
expression, with the 569 mutant locating between the wild-type
and the 391 mutant. The 569 mutant, possessing only partial
STAT5 signalling ability, was generally not well separated from
the wild-type or the 391 mutant. Moreover, while the metabolism
in mutant 391 is clearly different from that of the wild-type
littermates (Figure 4E) at 4 months of age and stays different up to
12 months of age, the metabolism of the 569 mutant mice changes
with the age of the mice. The younger 569 mutant mice with an
age up to 6 months have a metabolic fingerprint close to the wild-
type mice (Figure 4E), which is consistent with their microarray
profiling at 42 days of age (Figure 2A). On the other hand, the
metabolic fingerprint in the older 569 mice between 9 and 12
months has changed to resemble the 391 mutant mice (Figure 4E).
At this time they also became visibly obese (Figure 2B). It should
be noted that metabolic enzymes are often regulated by means
other than transcription, for example substrate availability,
enzyme half-life, changes in activity, or binding co-factors [29].
Thus, an analysis of predicted metabolic changes based on
microarray data alone does not provide the full picture, especially
Figure 5. Statistical analysis of metabolites in murine liver
tissue. (A) 1D proton HR-MAS NMR spectrum of murine liver tissue. The
identity of relevant metabolites is indicated. Glu: glutamate, Gln:
glutamine (B) Principal components analysis - scores plot of PC1 versus
PC2. Each data point represents one liver tissue sample. Green circles:
wild-type, red squares: 569 mutants, blue triangles: 391 mutants,
orange diamonds: wild-type on high-fat diet. (C) Principal components
analysis - loadings plot of PC1 versus PC2. Each data point represents one
bucket (with the chemical shift indicated explicitly). Several significant
metabolites are indicated explicitly. The model consists of 3 PCs and
represents data from 18 samples. Regions containing water, lactate and
glutamate/glutamine signals were excluded from the PCA.
doi:10.1371/journal.pone.0002764.g005
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Characterisation of metabolite levels are a more direct measure of
the actual metabolic changes, and it is recognised that metabo-
nomics provides a connection between differential mRNA
responses and the metabolic phenotype [30–33].
The NMR-metabonomic analysis identified taurine as the most
prominent metabolite able to distinguish between wild-type and
mutant mice, with urinary taurine levels being decreased in
mutants. This was in agreement with the microarray analysis,
which identified Csad (cysteine sulfinic acid dehydrogenase) as one
of the marker transcripts decreased in the mutant mice. As CSAD
is the rate-limiting enzyme in taurine biosynthesis [34], the
decreased transcript levels are concordant with the reduced
taurine levels observed in the metabonomic analysis (Supplemen-
tary Information Figure S1). The observed change is also
consistent with reduction in the STAT5 signalling in GHR
mutant mice, as Csad transcript levels were decreased in
STAT5A
2/2 mice [35]. Taurine is the best example of the
convergence of the two methods and the power of multivariate
statistics in this combined analytical approach.
Taurine is an important metabolite involved in the bile acid
synthesis pathway [34], osmoregulation and intracellular calcium
levels [36]. It is generally regarded as a sensitive marker indicating
changes in the liver metabolism [37]. Our microarray analysis has
identified altered metabolic transcripts in the liver, in particular in
lipid, energy, nucleic acid and sulphur metabolism. Moreover, our
previous and current analysis of the 569 mutant mice showed that
they develop obesity and insulin resistance later in life [19]. The
change observed in the metabolic profile of mutant 569 is
accompanied by an increase in fat depots (Figure 2D–E). Taurine
is related to the development of obesity, as its conjugation to bile
acids is the only mechanism of excretion of cholesterol, and thus
reduces serum levels of cholesterol in humans, in particular in low-
density lipoproteins (LDL) [38]. Decreased taurine levels will thus
lead to increased cholesterol retention. This links taurine
biosynthesis with the cholesterol and steroid metabolism, which
are also affected in the GHR mutant mice (Kerr, Lichanska,
Rowland, Waters, in preparation). In addition, taurine levels are
decreased in diabetic patients [39].
Most significantly, a vicious cycle involving obesity and taurine
has recently been discovered [28], implicating low levels of taurine
in the continuing maintenance of this condition. The concentra-
tion of taurine in the blood regulates positively the expression of
cysteine deoxygenase (CDO), one of the key enzymes involved in
taurine biosynthesis (Supplementary Information Figure S1,
schematic), in white adipose tissue. Thus, decreasing blood taurine
levels lead to less CDO, further decreasing the taurine concen-
tration. Importantly, taurine promotes fatty acid oxidation (b-
oxidation) and increases mitochondrial energy metabolism. A
depletion of taurine blood levels, resulting from deficient STAT5
generation would thus reduce b-oxidation, promoting further
obesity and creating the vicious cycle [28] (Supplementary
Information Figure S1, schematic).
High expression levels of Csad are found only in the liver and
kidney [40,41], while they are negligible in most other organs,
especially in muscle and adipose tissue, making any contributions
from transcript changes in these organs to the observed reduction
in urinary taurine levels highly unlikely. It is likely that both liver
and kidney contribute to urinary taurine under the control of GH,
since both tissues possess responsive GH receptors. Indeed, the
metabonomic analysis of liver tissue shows the same changes in
taurine levels as seen in the urine, i.e. taurine levels are reduced in
liver tissue of 391 mutant mice when compared to lean wild-type
mice (Figure 5BC). This result demonstrates directly that the
reduced urinary taurine levels in the mutant mice reflect decreased
hepatic taurine biosynthesis. In contrast, taurine levels are
increased in obese (fat fed) wild-type mice compared to their lean
counterparts (Figure 5BC). This shows that the effects of GHR
mutation are clearly different from the effects of obesity and that
the obesity in the mutant mice is likely to be a consequence of the
low taurine levels and the GHR mutations rather than the
converse. It is plausible that the increase in hepatic taurine levels
seen in fat-fed wild-type mice is a compensatory mechanism to
overcome the increased supply of dietary triglycerides by
promoting b-oxidation.
Indeed, while a reduction in b-oxidation would be expected in
obesity, we have observed an increase in expression of a number of
genes involved in fatty acid b-oxidation. Similar observations were
made previously by other groups [15,17,18] in animals deficient in
GH. Most of these transcripts are normalized by GH treatment.
The changes observed by ourselves and others are generally small,
1.5–2 fold between the wild-type and mutants or GH-deficient
animals, and may reflect the hepatic response to increased lipid
load resulting from upregulation of the CD36 transporter and
lipoprotein lipase expression evident in the microarray analysis
(19), leading to steatosis in older animals.
The increased lipid transport in the GHR mutant mice is likely
to create an increased demand for lecithin, which can be satisfied
by increased lecithin synthesis via glycine and choline, causing an
increased flux through the choline metabolism. This interpretation
is corroborated by increased urinary levels of TMA, dimethyla-
mine (DMA) and TMAO. Indeed, these three metabolites are the
second-most significant metabolites in the metabonomic analysis
after taurine. They can be made either via endogenous pathways
from choline or from dimethylglycine (Supplementary Information
Figure S1), or via exogenous pathways involving gut flora [42,43].
The increased flux through the endogenous glycine-choline
pathway is further substantiated by increased transcriptional levels
of FMO3 [44,45], the enzyme catalysing the conversion of TMA
to TMAO, and this enzyme was identified as one of our marker
genes (Figure 2A).
The increased flux through the choline metabolism is likely to
be further facilitated by the decreased taurine production. Due to
the feedback inhibition of CDO and the decreased levels of Csad
levels, the taurine precursor cysteine can be shunted through
alternative pathways, by being converted via serine to glycine and
then further into choline and lecithin as outlined above.
However, the metabonomic data suggest that the majority of
the cysteine is shunted into the biosynthesis of creatine, which
undergoes breakdown to creatinine (Supplementary Information
Figure S1). The urinary levels of both compounds were increased,
which can indicate an overflow of the serine to glycine pathway,
alteration of muscle metabolism, kidney function, or all of those.
Indeed it has been previously suggested that increased cysteine
synthesis is associated with hypercreatinuria [46]. Creatine is also
an important metabolite of energy metabolism because a
phosphorylated form of it (phosphocreatine) is able to phosphor-
ylate ADP to ATP [47], thereby generating energy reserves. The
excretion of creatinine is a sensitive marker for lean muscle mass
[48], which is in turn highly influenced by GH, and thus it could
be argued that the observed changes in creatine/creatinine
excretion are a result of changes in the muscle mass as result of
the disrupted GH signaling. However, the percentage of lean
muscle mass decreases in the GHR mutant mice, while excretion
of creatine and creatinine increases, meaning that the first
interpretation is more likely.
We anticipated abnormal energy metabolism, as 21% of
differentially expressed metabolic genes are involved in generation
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demonstrated changes in the urinary levels of TCA cycle
metabolites, with decreased urinary concentrations of citrate,
succinate, oxaloacetate and 2-oxoglutarate. These changes can
have a variety of reasons and are not straightforward to interpret,
as TCA cycle metabolites are also central metabolic branching
points for biosynthesis or breakdown of fatty acids as well as for
biosynthesis and breakdown of amino acids. A reduction in
urinary citrate can also indicate metabolic acidosis [49].
Correlating with the metabonomic observations, the microarray
analysis indicated alterations in the TCA cycle, albeit at low levels.
GH is known to regulate a number of TCA cycle enzymes, in
particular NADH-dependent isocitrate dehydrogenase, succinate
CoA ligase and fumarate hydratase [15,18].
One of the other categories changed in Gene Ontology analysis
was the metabolism of nucleic acids and its components (Table 1).
While we were unable to match the changes in gene expression to
a single pathway, there were indications of changes in pyrimidine
and to smaller extent in purine metabolism. The metabonomic
data showed increased urinary levels of allantoin, which is an
intermediate in purine metabolism. This is most likely the result of
an increased flux in purine metabolism, possibly due to increased
DNA breakdown and excretion via the xanthine-allantoin-urea
pathway. Alterations in this pathway would not be surprising, as it
has been described previously that in GH-deficient patients there
is increased excretion of urea [50,51] in fasting individuals, which
is overcome by GH replacement. Relevant to this is a large
increase in transcript levels of hydroxylamine oxidase (Hao3), for
which transcript levels were increased from 3.8 fold in mutant 569
to 11 fold in mutant 391 and GHR
2/2 mice. This would lead to
an increase in nitrite levels and consequently ammonia levels,
which can enter the urea cycle, further increasing urea excretion.
Conclusions
In this paper we have shown that truncations in the intracellular
domainoftheGHRthatimpairSTAT5signalinginparticularcause
dramatic metabolic changes, leading to obesity, and involving the
metabolism of the whole body, as evidenced by their consistency
between liver tissue and urine. The most prominent hallmarks of
these changes are a decrease in taurine levels and changes in choline
metabolism, characterized by increased levels of TMA, TMAO and
DMA. Both changes are connected via lipid transport pathways and
amino acid metabolism and support a potentially important role of
taurine in regulating b-oxidation.
We have also has shown how various parts of metabolism
interact with each other in response to altered hormonal levels.
The effects of GH on metabolism were always described as
complex, but they can be unraveled when global metabolism
analysis methods are used.
The multivariate statistical techniques analysing metabonomic
and gene expression data implicated the same biochemical
pathways. The convergence of both methods on the same
biochemical pathways underlines the complementarity of both
techniques and exemplifies the power of this combined approach.
Our results demonstrate that metabonomic data can be success-
fully linked with microarray results to develop a coherent picture
of physiological changes in response to a varying genetic
background, allowing a deeper understanding of systems biology.
Future studies combining more detailed genetic expression profile
data with established data of metabolic fluxes in tissues, metabolic
modelling, and metabonomic data will be useful in developing a
more detailed understanding of how changes in gene transcription
lead to the observed metabolic and systemic changes.
Materials and Methods
Animals
Animals were housed in an approved facility and treated as per
university guidelines with ethics approval from the University of
Queensland Animal Ethics Committee and the Australian Office
of the Gene Technology Regulator. Water and standard feed
pellets were available ab libitum under a 12 hr light/dark cycle at
20–22uC. Prior to urine collection, animals were fasted overnight
(16 hours), with water being provided ab libitum. Urine samples
were taken from 55 male mice aged from 2 to 12 months. The
mice were either wild-type C57Bl/6J (n=16), or had a truncation
in the GHR at lysine 569 together with conversion of tyrosines 539
and 545 to phenylalanine (mutant 569) (n=27) or had a
truncation in the GHR at lysine 391 (mutant 391) (n=12). In
addition, three animals/strain were used for gene expression
analysis using microarrays (see below). In addition, a second
cohort of male mice was used for metabonomic analysis of liver
tissue. This cohort comprised six wild-type C57Bl/6J mice fed on
standard chow, three wild-type mice fed on a special high-fat diet,
three mutant 569 mice and six mutant 391 mice, both fed on
standard chow. Mice were sactrificed at four months of age, the
left lateral lobe of the liver was removed immediately after killing,
snap frozen in liquid nitrogen, and stored at 280uC until required.
Creation of the two mutant strains is described in Rowland et al.
[19] and of the GHR
2/2 mice in Zhou et al. [52].
Adipose tissue analysis
Adipose tissue was dissected from two separate areas. Subcu-
taneous fat pads were obtained from the side of the back legs and
body, and renal adipose tissue was dissected from around the
kidneys. Each of the fat pads was weighed, and their weight
relative to the whole body weight is reported in the figures. For
each time point 4–8 animals/strain were sacrificed.
Microarray analysis
Mice were sacrificed at 42 days of age and the livers were
dissected directly into RNAlater solution (Ambion, Austin TX).
Total RNA was extracted using RNAqueous kit (Ambion)
according to the manufacturer’s instructions, quality of RNA
was confirmed by spectrophotometry and gel electrophoresis.
Probes were prepared as described in Rowland et al. [19]. Three
animals were used in each group. The samples were hybridized to
the Affymetrix U74v2A arrays.
The increases and decreases, as well as signal log ratios (SLRs,
equivalent of fold changes) were identified following standard
Affymetrix protocol with MAS 5.0, and then the comparisons were
loaded into DMT (Affymetrix), which allowed identification of
transcripts changing in the same direction and the number of
comparisons in which they change as described in [19]. In this
analysis a gene was scored as significantly changed in one group in
comparison to the other if it was changed in the same direction in
at least 8 out of 9 comparisons performed and the fold change was
above 1.5-fold. We used Anova to test the statistical significance of
the array data with a cut-off score of p,0.0005 and obtained a set
of 398 genes differentially expressed between the three groups.
Marker identification using microarrays
Microarray data were normalised using RMA [53] with qspline
normalisation of perfect match probes only. Median polish of the
results was used for a final expression value per probeset. The
resulting expression values were then analysed with GeneRaVE
algorithms [24], made available via the RChip library for the R
statistical language package, (RChip library and vignette are
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index.shtml). Genes were identified whose expression values could
be used to distinguish between the sets of array data. These genes
were removed from the dataset and a further set of classifiers were
obtained. This iterative process was continued until the predictive
power of the dataset was exhausted (11 rounds). Default settings
for GeneRaVE were used (kbess & bbess), as described in the
accompanying software vignette. The function ‘deleteRepeat’ was
used to extract multiple classifiers from the data using the
HGmultc method for fitting a multiclass logistic regression models
to our data. Ten-fold cross validation was also used to assess the
error associated with the chosen classifiers.
Functional classification and pathway analysis was performed
on the 399 genes identified in the previous study [19] as
differentially expressed. Gene Ontology analysis using NetAffx
GO Browser, and DAVID Functional Classification Tool [54]
were used to identify the main functional groups over-represented
among the differentially expressed genes. Pathway mapping was
performed using DAVID and the Pathway Miner (http://www.
biorag.org) [55]. For DAVID and NetAffx GO Browser we have
uploaded a gene list, in form of Affymetrix GeneIDs, of 399
differentially expressed genes, Biorag actually required GeneBank
accession numbers and log ratio changes for the 3 groups.
Array data are available from the NIH Gene Expression
Omnibus database (http://www.ncbi.nlm.nih.gov/geo/), with
accession numbers GSM15488, GSM15489, GSM15490,
GSM15491, GSM15492, GSM15493, GSM15494, GSM15495,
GSM15496, GSM15497, GSM15498, and GSM15499.
Preparation of urine samples
Urine was collected from animals into glass containers and
frozen immediately at 220uC. Samples were prepared for NMR
by diluting 200 ml mouse urine with 300 ml 0.1 M sodium
phosphate buffer, pH 7.4, and 50 mlD 2O. In cases, where less
than 200 ml mouse urine was available, urine was diluted with
H2O to 200 ml. Samples contained trimethylsilylpropionic acid
(TSP) for calibration of the
1H and
13C chemical shifts.
NMR spectroscopy of urine samples
NMR spectroscopy of mouse urine samples was carried out on a
Bruker AV500 NMR spectrometer equipped with a 5 mm self-
shielded z-gradient triple resonance probe and a sample changer.
All spectra were recorded at 298 K. 1D proton spectra were
measured with 256 scans and 64k resolution over a spectral width
of 14 ppm. To ensure solvent suppression of the water signal, 1D
spectra were measured with the noesypr1d pulse program (Bruker
pulse program library), using a mixing time of 150 ms. The water
signal was additionally suppressed by low-power continuous
irradiation on the water resonance during the mixing time and
the relaxation delay of 2.3 s.
In addition, the following 2D spectra were recorded on
representative samples of wild-type and 391 mice to facilitate the
assignment of signals in the 1D spectra: total correlation
spectroscopy (TOCSY), double-quantum filtered correlation
spectroscopy (DQF-COSY),
13C-heteronuclear single-quantum
correlation (
13C-HSQC),
13C-heteronuclear multiple bond corre-
lation (
13C-HMBC) and
13C-HSQC-TOCSY.
In all 2D spectra the
1H carrier frequency was positioned on the
water resonance. TOCSY [56] and DQF-COSY [57] spectra were
recorded for each sample with a resolution of 40966512 points and a
spectral width of 14.0 ppm. Quadrature detection in the indirect
dimension was achieved using the time-proportional phase incre-
mentation (TPPI) [58] method. Water suppression in the DQF-
COSY experiments was achieved using selective low-power irradi-
ation of the water resonance during the relaxation delay of 1.0 s. For
the TOCSY experiments a 3-9-19 WATERGATE scheme [59] was
used employing gradient pulses of ,6G c m
21 either side of a 10 kHz
3-9-19 binomial pulse. TOCSY experiments used a MLEV17
sequence [60] of 80 ms duration for isotropic mixing.
13C-HSQC [61,62] spectra were recorded with a resolution of
40966256 data points. The spectral width was 14 ppm for
1Ha n d
100 ppm for
13Cw i t ht h e
13C carrier frequency positioned at
45 ppm.
13C-HSQC-TOCSY [63] spectra were measured with
40966256 data points,128 scans,and spectral widthsof 14ppm and
200 ppm in
1Ha n d
13C, respectively. Isotropic mixing was achieved
with a DIPSI2 sequence [64] of 80 ms duration. The
13C-HMBC
[65,66] spectra were measured with 40966256 data points, 128
scans, and spectral widths of 14 ppm and 200 ppm in
1Ha n d
13C,
respectively. A relaxation delay of 2.0 s was used, and the transfer
delay was optimized for indirect coupling constants of 6 Hz.
HR-MAS NMR spectroscopy of liver tissue
For each sample about 50 mg of liver tissue were placed in a
4 mm reduced volume 50 ml zirconia rotor with a teflon top insert
and a Kel-F rotor cap (Bruker Biospin, Germany). All experiments
were carried out on a Bruker AV700 spectrometer, equipped with
a 4 mm HR-MAS triple resonance probe with z-gradients, at a
sample spinning rate of 8 kHz. 1D spectra were aquired with the
standard cpmgpr1d pulse program, using a rotor-synchronised
Carr-Purcell-Meiboom-Gill sequence [90u-(t-180u-t)n-acquisition]
of 20 ms duration (n=80) to suppress signals from macromole-
cules and other substances with short T2 values. The refocusing
delay t was set to 125 ms to match the rotation speed of the rotor.
Proton 1D spectra were measured unlocked with 128 scans and
32k resolution over a spectral width of 15 ppm. The water signal
was additionally suppressed by continuous low-power irradiation
on the water resonance during the relaxation delay of 3.0 s. The
total acquisition time for each spectrum was 11 min.
Processing of spectra
All NMR spectra were processed with TopSpin (Bruker Biospin
GmbH,Rheinstetten,Germany).1Dspectrawereprocessedtoasize
of 64k after multiplying with an exponential window function.
Spectra were manually phase and baseline corrected, and chemical
shiftswerereferencedtotheTSPsignalinthecaseofurinespectraor
lactate in the case of HR-MAS spectra of liver tissue.
Homonuclear 2D spectra were processed to a size of
409661024 data points. Prior to Fourier transformation, a
Lorentz to Gauss transformation with a line broadening factor
of of 210 Hz and a GB of 0.1 was applied in the direct dimension,
while in the indirect dimension data were linearly predicted, using
30 poles, and then multiplied with a squared sine bell function,
shifted by p/2.
Heteronuclear 2D spectra were processed in a similar fashion to
a data matrix size of 20486512 data points, except that the
window function in the direct dimension was a squared sine bell
function, shifted by p/2. A magnitude calculation was applied in
the indirect dimension to all
13C-HMBC spectra after Fourier
transformation
Data reduction
The 1D spectra of mouse urine were data reduced over the shift
range of d=10.0–0.5 ppm into spectral integral regions (‘‘buck-
ets’’) of 0.05 ppm width, using AMIX3.6.6 (Bruker Biospin
GmbH, Rheinstetten, Germany). The regions d=4.6–5.0 ppm
and d=5.5–6.5 ppm were excluded to avoid artefacts from
varying water suppression and cross-saturation through chemical
exchange in the urea signal. NMR signals were integrated for each
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spectrum. A second bucket table was constructed in a similar
fashion, additionally excluding the regions of 1.22–1.16 ppm and
3.7–3.6 ppm to exclude ethanol signals.
A similar procedure was applied for the HR-MAS spectra of
mouse liver tissue. Buckets ranged from d=10.0–0.2 ppm with a
bucket width of 0.1 ppm. The region d=4.5–6.5 ppm was excluded
to avoid artefacts from varying water suppression. A second bucket
table was constructed in a similar fashion, additionally excluding the
regions of d=1.9–2.5 ppm, and d=1.2–1.5 ppm to avoid artefacts
from shifts in the signals of lactate and glutamate/glutamine that
otherwise dominated the analysis.
Principal components analysis (PCA)
PCA was performed in AMIX, using the data from the
bucketed 1D spectra of mouse urine. A first PCA model was
constructed using all samples. The scores plots of PC1 versus PC2
and PC1 versus PC3 were inspected for differences between the
different mouse strains. Samples that constituted outliers were
identified in AMIX by cross-validation, removed from the model,
and a further round of PCA was performed. The refined model
contained seven principal components (PCs) and comprised data
from 44 urine samples.
A second PCA model was constructed in a similar fashion from
the bucket table, additionally excluding ethanol signals. The final
model contained seven PCs, explaining 90.8% of total variance,
and comprised data from 48 urine samples.
PCAwasalsoperformedsimilarlywiththedatafromthebucketed
1D spectra of mouse liver tissue. The PCA model contained all
samples and three PCs. As this analysis was dominated by large
variations in the signals of lactate and glutamate/glutamine, a
refined PCA was performed, additionally excluding these signals.
The final model contained three PCs, explaining 92.0% of total
variance, and comprised data from 18 tissue samples.
Partial Least Squares Discriminant Analysis (PLS-DA)
PLS-DA was performed in AMIX, using data from the
bucketed 1D spectra of urine and group IDs of 0 (wild-type
mice), 1 (569 mice), and 2 (391 mice) as Y table. Buckets
containing signals of water, urea and ethanol were excluded from
the analysis as described above. Samples that constituted outliers
were identified in AMIX by cross-validation, removed from the
model, and further round of PLS-DA was performed. The refined
model comprised data from 54 urine samples and contained seven
PLS components, explaining 84.2% of total X-variance and
87.5% of total Y-variance with an rmsec value of 0.249. In
addition, the mouse strains were compared pairwise in three
separate PLS-DAs. These analyses were performed similarly to the
PLS-DA comparing all three mouse strains.
Metabolic trajectories for each mouse strain were constructed
by averaging the PLS1 scores for groups of mice with similar age.
Age stages where only one single mouse was available were
included in the next closest age group if their ages did not differ by
more than half a month, otherwise they were omitted from the
analysis. In addition, the 2s standard deviation from the mean
PLS1 scores was calculated to indicate the possible bandwidth of
the metabolic trajectories.
Identification of metabolites
Metabolites were identified in the NMR spectra by comparing
their
1Ha n d
13C chemical shifts and coupling patterns with
corresponding values of metabolites from previously published data
[26,27] and from publicly accessible data banks, such as the
BioMagRes data bank (http://www.bmrb.wisc.edu), the Metabo-
lomics Database of Linkoping (MDL) (http://mdl.imv.liu.se), or the
Human Metabolome Data Bank (http://www.hmdb.ca). In addi-
tion, the information contained in the high-resolution 2D NMR
spectra (proton-proton couplings, direct and indirect proton-carbon
couplings) was used for the identification of metabolites.
Supporting Information
Figure S1 Metabolic Pathways affected by GHR mutations. Individual
enzymes are depicted in italics, and sections of metabolism in bold
and boxed.Metaboliteswith increased concentration inthe mutants,
as detected by the metabonomic study, are indicated in green and
marked by plus signs, whereas metabolites with decreased
concentration in the mutants are indicated in red and marked by
minus signs. Enzymes in the pathways with increased or decreased
expression levels areindicatedsimilarly.The feedbackloopsbetween
taurine levels, CDO levels, b-oxidation and obesity are indicated by
dashed connections in blue. Arrowheads indicate positive feedback
and bar heads negative (inhibitory) feedback. The two negative
feedback connections beween taurine and fat levels form a vicious
cycle. Enzyme abbreviations: Csad - cysteine sulfinic acid decarbox-
ylase, Pdha1 - pyruvate dehydrogenase alpha 1, Idh2 -i s o c i t r a t e
dehydrogenase 2, Suclg1 - succinate-CoA ligase, Sdhb -s u c c i n a t e
dehydrogenase complex, subunit B, Fmo3 - flavin containing
monooxygenase 3, LCAT - lecithin cholesterol acyltransferase, and
CDO - cysteine dioxygenase 1.
Found at: doi:10.1371/journal.pone.0002764.s001 (0.63 MB TIF)
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